(Mark One) | |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||
300 East Lombard Street, Suite 1710 | ||||||
(Zip Code) | ||||||
(Address of principal executive office (US)) | ||||||
(Registrant's telephone number, including area code) | ||||||
Securities registered pursuant to section 12(b) of the Act | ||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
☑ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ||
Emerging growth company |
Page | |||
Item 1. | |||
Item 2. | |||
Item 3. | |||
Item 4. | |||
Item 1. | |||
Item 1A. | |||
Item 2. | |||
Item 3. | |||
Item 4. | |||
Item 5. | |||
Item 6. | |||
Three months ended March 31, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Revenue | 2 | |||||
Cost of sales (excluding depreciation and amortization) | ( | ( | ||||
Depreciation and amortization | ( | ( | ||||
Selling and administrative expenses | ( | ( | ||||
Research and development expenses | ( | ( | ||||
Other gains and losses – net | 4 | ( | ||||
Finance costs – net | 5 | ( | ( | |||
Income before tax | ||||||
Income tax expense | 6 | ( | ( | |||
Net income | ||||||
Attributable to: | ||||||
Equity holders of Constellium | ||||||
Non-controlling interests | ( | |||||
Net income | ||||||
Earnings per share attributable to the equity holders of Constellium (in U.S. dollars) | Notes | |||||
Basic | 7 | |||||
Diluted | 7 |
Three months ended March 31, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Net income | ||||||
Other comprehensive (loss) / income | ||||||
Net change in post-employment benefit obligations | ( | ( | ||||
Income tax on net change in post-employment benefit obligations | ||||||
Net change in cash flow hedges | 12 | ( | ||||
Income tax on cash flow hedges | ( | |||||
Currency translation adjustments | ( | |||||
Other comprehensive (loss) / income | ( | |||||
Total comprehensive income | ||||||
Attributable to: | ||||||
Equity holders of Constellium | ||||||
Non-controlling interests | ( | |||||
Total comprehensive income | ||||||
(in millions of U.S. dollars) except share data and as otherwise stated | Notes | At March 31, 2026 | At December 31, 2025 | |||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
Trade receivables and other, net | 8 | |||||
Inventories | 9 | |||||
Fair value of derivatives instruments and other financial assets | ||||||
Total current assets | ||||||
Non-current assets | ||||||
Property, plant and equipment, net | ||||||
Goodwill | ||||||
Intangible assets, net | ||||||
Deferred tax assets | ||||||
Trade receivables and other, net | 8 | |||||
Fair value of derivatives instruments | 12 | |||||
Total non-current assets | ||||||
Total assets | ||||||
Liabilities | ||||||
Current liabilities | ||||||
Trade payables and other | 10 | |||||
Current portion of long-term debt | 11 | |||||
Fair value of derivatives instruments | 12 | |||||
Income tax payable | ||||||
Pension and other benefit obligations | ||||||
Provisions | 14 | |||||
Total current liabilities | ||||||
Non-current liabilities | ||||||
Trade payables and other | 10 | |||||
Long-term debt | 11 | |||||
Fair value of derivatives instruments | 12 | |||||
Pension and other benefit obligations | ||||||
Provisions | 14 | |||||
Deferred tax liabilities | ||||||
Total non-current liabilities | ||||||
Total liabilities | ||||||
Commitments and contingencies | 14 | |||||
Shareholders' equity | ||||||
Ordinary shares, par value € at December 31, 2025; 31, 2026 and at December 31, 2025, respectively | ||||||
Additional paid in capital | ||||||
Accumulated other comprehensive income | 15 | |||||
Retained earnings | ||||||
Treasury shares 2025 | ( | ( | ||||
Equity attributable to equity holders of Constellium | ||||||
Non-controlling interests | ||||||
Total equity | ||||||
Total equity and liabilities |
in millions of U.S. dollars, except share amounts | Ordinary shares outstanding | Ordinary shares | Treasury shares | Accumulated other comprehensive income / (loss) | Additional paid in capital | Retained earnings | Non- controlling interests | Total equity | ||||||||
At January 1, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | ( | ||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive (loss) / income | — | — | — | ( | — | ( | ||||||||||
Share issuance | — | — | — | — | — | — | — | |||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | ( | — | |||||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At March 31, 2026 | ( | |||||||||||||||
in millions of U.S. dollars, except share amounts | Ordinary shares outstanding | Ordinary shares | Treasury shares | Accumulated other comprehensive income / (loss) | Additional paid in capital | Retained earnings | Non- controlling interests | Total equity | ||||||||
At January 1, 2025 | ( | ( | ||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive income | — | — | — | — | — | — | ||||||||||
Total comprehensive income | — | — | — | — | ||||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | ( | — | |||||||||||
Other | — | — | — | — | ( | — | ||||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At March 31, 2025 | ( | ( |
Three months ended March 31, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Net income | ||||||
Adjustments | ||||||
Depreciation and amortization | 3 | |||||
Impairment of assets | 3 | |||||
Pension and other long-term benefits | ||||||
Finance costs - net | 5 | |||||
Income tax expense | ||||||
Unrealized (gains) /losses on derivatives - net and from remeasurement of monetary assets and liabilities - net | ( | |||||
Other - net | ||||||
Changes in working capital | ||||||
Inventories | ( | ( | ||||
Trade receivables | ( | ( | ||||
Trade payables | ||||||
Other | ( | ( | ||||
Change in provisions | ( | |||||
Pension and other long-term benefits paid | ( | ( | ||||
Interest paid | ( | ( | ||||
Income tax paid | ( | ( | ||||
Net cash flows from operating activities | ||||||
Purchases of property, plant and equipment | 3 | ( | ( | |||
Property, plant and equipment inflows | 3 | |||||
Collection of deferred purchase price receivable | 8 | |||||
Net cash flows used in investing activities | ( | ( | ||||
Repurchase of ordinary shares | ( | ( | ||||
Repayments of long-term debt | ( | ( | ||||
Net change in revolving credit facilities and short-term debt | ||||||
Finance lease repayments | ( | ( | ||||
Transactions with non-controlling interests | ( | ( | ||||
Other financing activities | ( | |||||
Net cash flows from / (used in) financing activities | ( | |||||
Net increase / (decrease) in cash and cash equivalents | ( | |||||
Cash and cash equivalents - beginning of year | ||||||
Net increase / (decrease) in cash and cash equivalents | ( | |||||
Effect of exchange rate changes on cash and cash equivalents | ( | |||||
Cash and cash equivalents - end of period | ||||||
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Aerospace rolled products | ||||
Transportation, industry, defense and other rolled products | ||||
Packaging rolled products | ||||
Automotive rolled products | ||||
Specialty and other thin-rolled products | ||||
Automotive extruded products | ||||
Other extruded products | ||||
Total revenue | ||||
Three months ended March 31, | ||||||||||
2026 | 2025 | |||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | H&C (B) | A&T | P&ARP | AS&I | H&C (B) | ||
Segment revenue | ||||||||||
Inter-segment elimination | ( | ( | ( | ( | ( | ( | ||||
External revenue | ||||||||||
Cost of metal | ( | ( | ( | ( | ( | ( | ||||
Production costs | ( | ( | ( | ( | ( | ( | ( | ( | ||
Other segment expenses (A) | ( | ( | ( | ( | ( | ( | ( | ( | ||
Segment Adjusted EBITDA | ( | ( | ||||||||
Three months ended March 31, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
A&T | ||||||
P&ARP | ||||||
AS&I | ||||||
H&C (A) | ( | ( | ||||
Segment Adjusted EBITDA | ||||||
Metal price lag (B) | ||||||
Depreciation and amortization | ( | ( | ||||
Impairment of assets | ( | |||||
Share based compensation | 16 | ( | ( | |||
Pension and other post-employment benefits - non - operating gains | ||||||
Restructuring costs | ( | ( | ||||
Unrealized gains / (losses) on derivatives | ( | |||||
Unrealized exchange gains / (losses) from the remeasurement of monetary assets and liabilities – net | ( | |||||
Other (C) | ||||||
Expenses on factoring arrangements | 8 | ( | ( | |||
Finance costs – net | 5 | ( | ( | |||
Income before tax | ||||||
Income tax expense | 6 | ( | ( | |||
Net income | ||||||
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
A&T | ( | ( | ||
P&ARP | ( | ( | ||
AS&I | ( | ( | ||
Total capital expenditures (A) | ( | ( | ||
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
A&T | ( | ( | ||
P&ARP | ( | ( | ||
AS&I | ( | ( | ||
H&C (A) | ( | ( | ||
Total depreciation, amortization and impairment expense | ( | ( | ||
(in millions of U.S. dollars) | At March 31, 2026 | At December 31, 2025 | ||
A&T | ||||
P&ARP | ||||
AS&I | ||||
H&C (A) | ||||
Deferred income tax assets | ||||
Cash and cash equivalents | ||||
Fair value of derivatives instruments and other financial assets | ||||
Total assets |
Three months ended March 31, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Operating income and expenses | ||||||
Realized gains / (losses) on derivatives (A) | ||||||
Unrealized gains / (losses) on derivatives at fair value through profit and loss - net (A) | 12 | ( | ||||
Unrealized exchange gains / (losses) from the remeasurement of monetary assets and liabilities – net | ( | |||||
Impairment of assets | ( | |||||
Restructuring costs | ( | ( | ||||
Result from the flood in Valais | 3 | |||||
Non-operating income and expenses | ||||||
Expenses on factoring arrangements | 8 | ( | ( | |||
Pension and other post-employment benefits | 13 | |||||
Other | ||||||
Total other gains and losses - net | ( | |||||
Three months ended March 31, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Interest expense on borrowings (A) | ( | ( | ||||
Interest cost on pension and other long-term benefits | 13 | ( | ( | |||
Realized and unrealized (losses) / gains on debt derivatives at fair value (B) | 12 | ( | ||||
Realized and unrealized exchange (losses) / gains on financing activities - net (B) | ( | |||||
Other finance expenses | ( | ( | ||||
Capitalized borrowing costs (C) | ||||||
Finance expenses | ( | ( | ||||
Finance costs - net | ( | ( | ||||
Three months ended March 31, | ||||
(in millions of U.S. dollars except share and per share amounts ) | 2026 | 2025 | ||
Numerator: | ||||
Net income attributable to equity holders of Constellium | ||||
Denominator: | ||||
Basic - weighted-average ordinary shares outstanding | ||||
Dilutive effect of non-vested restricted stock units and performance-based restricted stock units | ||||
Diluted - weighted-average ordinary shares, of restricted stock units and performance- based restricted stock units | ||||
Basic earnings per share | $ | $ | ||
Diluted earnings per share | $ | $ | ||
At March 31, 2026 | At December 31, 2025 | |||
(in millions of U.S. dollars) | Current | Current | ||
Trade receivables - gross | ||||
Allowance for credit losses | ( | ( | ||
Total trade receivables - net | ||||
Total other receivables | ||||
Total trade receivables and other |
(in millions of U.S. dollars) | At March 31, 2026 | At December 31, 2025 | ||
Finished goods | ||||
Work in progress | ||||
Raw materials | ||||
Stores and supplies | ||||
Total inventories |
At March 31, 2026 | At December 31, 2025 | |||
(in millions of U.S. dollars) | Current | Current | ||
Trade payables | ||||
Employees' entitlements | ||||
Other payables | ||||
Total other | ||||
Total trade payables and other |
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Contract liabilities and other liabilities to customers at January 1, | ||||
Revenue deferred to contract liabilities | ||||
Revenue recognized from contract liabilities | ( | ( | ||
Effect of changes in foreign currency rates and other changes | ( | |||
Contract liabilities and other liabilities to customers at March 31, | ||||
At March 31, 2026 | At December 31, 2025 | |||||||||
(in millions of U.S. dollars) | Nominal Value in Currency | Nominal rate | Effective rate | Face Value | Debt issuance costs | Accrued interest | Carrying value | Carrying value | ||
Secured Pan-U.S. ABL (due 2029) | $ | Floating | ||||||||
Senior Unsecured Notes | ||||||||||
Issued June 2020 and due 2028 | $ | ( | ||||||||
Issued February 2021 and due 2029 | $ | ( | ||||||||
Issued June 2021 and due 2029 | € | ( | ||||||||
Issued August 2024 and due 2032 | $ | ( | ||||||||
Issued August 2024 and due 2032 | € | ( | ||||||||
Finance lease liabilities | ||||||||||
Other loans | ( | |||||||||
Total debt | ( | |||||||||
Of which non-current | ||||||||||
Of which current (A) | ||||||||||
At March 31, 2026 | At December 31, 2025 | |||||||||||
(in millions of U.S. dollars) | Non- current | Current | Total | Non- current | Current | Total | ||||||
Derivatives that qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Derivatives that do not qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Currency net debt derivatives | ||||||||||||
Energy derivatives | ||||||||||||
Metal derivatives | ||||||||||||
Fair value of derivatives instruments - assets | ||||||||||||
Derivatives that do not qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Energy derivatives | ||||||||||||
Metal derivatives | ||||||||||||
Fair value of derivatives instruments - liabilities | ||||||||||||
At March 31, 2026 | At December 31, 2025 | |||||||||||||||
(in millions of U.S. dollars) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||
Fair value of derivatives instruments - assets | ||||||||||||||||
Fair value of derivatives instruments - liabilities | ||||||||||||||||
Sold currencies | Maturity Year | Less than 1 year | Over 1 year | |||
USD | 2026-2031 | |||||
CHF | 2026-2029 | |||||
CZK | 2026 | |||||
Other currencies | 2026-2027 |
Purchased currencies | ||||||
USD | 2026-2027 | |||||
CHF | 2026-2028 | |||||
CZK | 2026-2027 | |||||
Other currencies | 2026 |
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Derivatives that do not qualify for hedge accounting | ||||
Included in Other gains and losses - net | ||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||
Unrealized (losses) / gains on foreign currency derivatives - net (B) | ( | |||
Derivatives that qualify for hedge accounting | ||||
Included in Other comprehensive income | ||||
Unrealized (losses) / gains on foreign currency derivatives - net | ( | |||
(Losses) / gains reclassified from cash flow hedge reserve to the Consolidated Income Statement | ( | |||
Included in Revenue (C) | ||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||
Unrealized gains on foreign currency derivatives - net | ||||
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Derivatives that do not qualify for hedge accounting | ||||
Included in Finance costs - net | ||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||
Unrealized gains / (losses) on foreign currency derivatives - net | ||||
Total | ( | |||
(in millions of U.S. dollars) | Maturity Year | Less than 1 year | Over 1 year | |||
Metal | 2026-2028 | ( | ||||
Natural gas | 2026-2028 |
Three months ended March 31, | ||||
(in millions of U.S. dollar) | 2026 | 2025 | ||
Derivatives that do not qualify for hedge accounting | ||||
Included in Other gains and losses - net | ||||
Realized gains / (losses) on commodities derivatives - net (A) | ||||
Unrealized gains / (losses) on commodities derivatives - net | ( | |||
Three months ended March 31, | |||||||
2026 | 2025 | ||||||
(in millions of U.S. dollars) | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | |||
Current service cost | ( | ( | ( | ( | |||
Interest cost | ( | ( | ( | ( | |||
Expected return on plan assets | |||||||
Amortization of past service gain | |||||||
Total net pension and other long-term benefit cost | ( | ( | |||||
At March 31, 2026 | At December 31, 2025 | |||||||
(in millions of U.S. dollars) | Current | Non-current | Current | Non-current | ||||
Close down and environmental remediation costs | ||||||||
Restructuring costs | ||||||||
Legal claims and other costs | ||||||||
Total provisions | ||||||||
Three months ended March 31, 2026 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At January 1, 2026 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | ( | ||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
At March 31, 2026 | ( | |||||||
Three months ended March 31, 2025 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At January 1, 2025 | ( | ( | ( | |||||
Other comprehensive income / (loss) before reclassification | ||||||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ||||||
Amounts reclassified from accumulated other comprehensive income / (loss) to retained earnings | ||||||||
At March 31, 2025 | ( | ( | ( | |||||
2026 PSUs | ||
Fair value at grant date (in dollars) | ||
Share price at grant date (in dollars) | ||
Dividend yield | ||
Expected volatility (A) | ||
Risk-free interest rate (US government bond yield) |
Three months ended March 31, 2026 | ||||
(as a % of total) | Revenue | Segment Adjusted EBITDA | ||
A&T | 25% | 39% | ||
P&ARP | 60% | 58% | ||
AS&I | 17% | 9% | ||
H&C (1) | —% | (6)% | ||
Total | 100% | 100% | ||
Three months ended March 31, | Percent changes QTD | |||||
(U.S. dollars per ton) | 2026 | 2025 | 2026 vs 2025 | |||
Average LME transaction price | 3,199 | 2,627 | 22% | |||
Average Midwest premium | 2,296 | 712 | 222% | |||
Average all-in aluminum price U.S. | 5,495 | 3,339 | 65% | |||
Average LME transaction price | 3,199 | 2,627 | 22% | |||
Average Rotterdam premium | 392 | 290 | 35% | |||
Average all-in aluminum price Europe | 3,591 | 2,917 | 23% | |||
Three months ended March 31, | ||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | ||||||
Revenue | 2,461 | 100% | 1,979 | 100% | ||||
Cost of sales (excluding depreciation and amortization) | (2,041) | 83% | (1,716) | 87% | ||||
Depreciation and amortization | (83) | 3% | (78) | 4% | ||||
Selling and administrative expenses | (97) | 4% | (78) | 4% | ||||
Research and development expenses | (13) | 1% | (13) | 1% | ||||
Other gains and losses – net | 73 | 3% | (5) | —% | ||||
Finance costs – net | (28) | 1% | (27) | 1% | ||||
Income before tax | 272 | 11% | 62 | 3% | ||||
Income tax expense | (76) | 3% | (24) | 1% | ||||
Net income | 196 | 8% | 38 | 2% | ||||
Shipment volumes (in kt) | 370 | n/a | 372 | n/a | ||||
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Realized gains / (losses) on foreign currency derivatives - net | 1 | (3) | ||
Realized gains on commodities derivatives - net | 37 | 9 | ||
Realized gains / (losses) on derivatives | 38 | 6 | ||
Unrealized (losses) / gains on foreign currency derivatives - net | (12) | 15 | ||
Unrealized gains / (losses) on commodities derivatives - net | 54 | (27) | ||
Unrealized gains / (losses) on derivatives at fair value through profit and loss - net | 42 | (12) | ||
Three months ended March 31, | ||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | ||||||
A&T | 609 | 25% | 468 | 24% | ||||
P&ARP | 1,477 | 60% | 1,187 | 60% | ||||
AS&I | 415 | 17% | 381 | 19% | ||||
H&C (1) | 2 | —% | — | —% | ||||
Inter-segment eliminations | (42) | n.m | (57) | n.m | ||||
Total revenue | 2,461 | 100% | 1,979 | 100% | ||||
Three months ended March 31, | ||||||||
(in kt and as a % of shipments) | 2026 | 2025 | ||||||
A&T | 60 | 16% | 51 | 14% | ||||
P&ARP | 261 | 71% | 269 | 72% | ||||
AS&I | 51 | 14% | 52 | 14% | ||||
Inter-segment eliminations | (2) | n.m | — | n.m | ||||
Total shipments | 370 | 100% | 372 | 100% | ||||
Three months ended March 31, | ||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | ||||||
A&T | 102 | 17% | 82 | 18% | ||||
P&ARP | 151 | 10% | 60 | 5% | ||||
AS&I | 24 | 6% | 16 | 4% | ||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | |||
Segment Adjusted EBITDA for the three months ended March 31, 2025 | 82 | 60 | 16 | |||
Volume | 32 | (6) | (4) | |||
Price and product mix | (2) | 26 | (2) | |||
Costs | (16) | 65 | 11 | |||
Foreign exchange and other | 6 | 6 | 3 | |||
Segment Adjusted EBITDA for the three months ended March 31, 2026 | 102 | 151 | 24 |
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Net Cash Flows from / (used in) | ||||
Operating activities | 73 | 58 | ||
Investing activities | (68) | (59) | ||
Financing activities | 20 | (26) | ||
Net (decrease) / increase in cash and cash equivalents, excluding the effect of exchange rate changes | 25 | (27) | ||
Three months ended March 31, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Net income | 196 | 38 | ||
Income tax expense | 76 | 24 | ||
Finance costs – net | 28 | 27 | ||
Expenses on factoring arrangements | 4 | 5 | ||
Depreciation and amortization | 83 | 78 | ||
Restructuring costs | 3 | 1 | ||
Unrealized gains on derivatives | (42) | 12 | ||
Unrealized exchange gains from the remeasurement of monetary assets and liabilities – net | (1) | 1 | ||
Pension and other post-employment benefits - non - operating gains | (3) | (3) | ||
Share based compensation | 11 | 6 | ||
Gains / (losses) on disposal | — | — | ||
Other (A) | — | (3) | ||
Adjusted EBITDA1 | 359 | 186 | ||
of which Metal price lag (B) | 97 | 39 | ||
Period | Total number of shares purchased | Average price paid per share (in U.S. dollars) | Total number of shares purchased as part of publicly announced plans or programs | Maximum approximate dollar value of shares that may yet be purchased under the program | ||||
January 1 - January 31, 2026 | 354,931 | 20.48 | 354,931 | 98,851,993 | ||||
February 1 - February 28, 2026 | 509 | 21.99 | 509 | 98,840,801 | ||||
March 1 - March 31, 2026 | 796,635 | 25.10 | 796,635 | 78,841,643 | ||||
Total | 1,152,075 | 1,152,075 | 78,841,643 |
Exhibit | Description |
10.1 | |
10.2 | |
10.3 | |
31.1 | |
31.2 | |
32.1 | |
32.2 | |
101.INS | Inline XBRL Instance Document** |
101.SCH | Inline XBRL Taxonomy Extension Schema Document** |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document** |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document** |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document** |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document** |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)** |
Constellium SE | |||
Date: | April 29, 2026 | By: | /s/ Ingrid Joerg |
Name: Ingrid Joerg | |||
Title: Chief Executive Officer and Director | |||
Date: | April 29, 2026 | By: | /s/ Jack Guo |
Name: Jack Guo | |||
Title: Executive Vice President & Chief Financial Officer |